株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アジア太平洋地域のぜんそく治療薬市場

Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market

発行 GlobalData 商品コード 520763
出版日 ページ情報 英文 134 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.87円で換算しております。
Back to Top
アジア太平洋地域のぜんそく治療薬市場 Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market
出版日: 2017年06月01日 ページ情報: 英文 134 Pages
概要

アジア太平洋地域のぜんそく治療薬の市場規模は、2016年には41億米ドル、2023年には60億米ドルと、5.4%のCAGR (複合年間成長率) で拡大する見通しです。市場成長の一因として、高齢者人口の増加により、ぜんそくの有病者数も増加したことが挙げられます。

当レポートでは、アジア太平洋地域諸国における喘息治療薬のの市場について分析し、疾患の概要や現在の治療薬の開発・活用状況、現在上市済み/パイプライン上 (治験中) の主要製品の概略、今後の市場収益額の見通し (地域全体/主要国)、企業間競争の現状、資本取引・事業協力の動きなどを調査しております。

第1章 目次

第2章 イントロダクション

  • 疾患の概略
  • 疫学
  • 症状
  • 病因と病態生理
  • 診断方法
  • 病期
  • 予後
  • 治療ガイドラインおよびオプション
    • 治療アルゴリズム
    • 薬物治療
    • 非薬物治療

第3章 上市済み製品

  • 概要
  • ぜんそく維持療法向けICS (吸入コルチコステロイド)
    • Arnuity (フロ酸フルチカゾン) - GlaxoSmithKline
  • ぜんそく維持療法向けの、ICSとLABA (長時間作用型β2刺激薬) の併用療法
    • Seretide/Adoair (プルピオン酸フルチカゾン、キシナホ酸サルメテロール) - GlaxoSmithKline
    • Symbicort (ブデソニド・フマル酸フォルモテロール) - AstraZeneca (アステラス製薬との共同販売)
    • Relvar/Breo (ビランテロールトリフェニル酢酸塩、フロ酸フルチカゾン) - GlaxoSmithKline
    • Flutiform (プルピオン酸フルチカゾン、フマル酸フォルモテロール) - SkyePharma
  • ぜんそく維持療法向けの、ICSまたはICS-LABAへの付加療法
    • Xolair (オマリズマブ) - Novartis and Genentech
    • モンテルカストナトリウム - Merck & Co
    • Spiriva (臭化チオトロピウム) - Boehringer Ingelheim
    • Nucala (メポリズマブ) - GlaxoSmithKline
  • 上市済み製品の効能・安全性の比較分析

第4章 パイプライン製品分析

  • 概要
  • パイプライン製品:開発段階別、分子の種類別、投薬経路別、プログラムの種類別
  • パイプライン製品:標的分子別
  • 将来有望なパイプライン分子
    • レスリズマブ - Teva Pharmaceutical
    • デュピルマブ - Regeneron/Sanofi
    • トラロキヌマブ - AstraZeneca
    • ベンラリズマブ - AstraZeneca
    • フェビピプラント - Novartis
  • パイプライン製品の効能・安全性の相互比較
  • 製品競争力の枠組み

第5章 治験の分析

  • 失敗率
    • 全体的な失敗率
    • 相 (フェーズ) 別・分子種類別の失敗率
    • 相別・標的分子別の失敗率
  • 治験期間
    • 分子種類別の治験期間
    • 標的分子別の治験期間
  • 治験規模
    • 治験1回当たり参加患者数:分子種類・標的分子・治験段階別
    • 製品1品目当たり参加患者数:分子種類・標的分子・治験段階別
  • サマリー

第6章 複数シナリオの市場予測

  • 各地域の市場
  • アジア太平洋地域市場
  • インド
    • 治療薬の利用パターン
    • 年間治療費
    • 市場規模
  • 中国
  • オーストラリア
  • 韓国
  • 日本

第7章 市場促進・抑制要因

  • 市場促進要因
    • 人口高齢化とぜんそくのリスク要因
    • 有望なパイプライン製品と、ファースト・イン・クラス分子の上市
    • 高価格製品の新規参入
    • 医療保険改革の進展に伴う市場成長
  • 市場抑制要因
    • ジェネリック医薬品による売上高の縮小
    • 従来型の医薬品との競合
    • 治療レジメンの遵守
    • 背景にある病因に対する理解不足
    • 高価格の生物製剤:認知度の低さと購買余力の小ささ

第8章 資本取引および戦略的統合

  • ライセンス取引
    • 取引金額:地域別
    • 取引件数 (公開/非公開、年度別) と総取引額
    • 取引金額:治験段階別、分子の種類別、標的分子別
    • 主なライセンス取引
  • 共同開発取引
    • 取引金額:地域別
    • 取引件数 (公開/非公開、年度別) と総取引額
    • 取引金額:治験段階別、分子の種類別、標的分子別
    • 主な共同開発取引

第9章 付録

図表一覧

目次
Product Code: GBIHC386MR

Executive Summary

Asthma is a common chronic inflammatory disease of the airways. It is characterized by recurrent attacks of breathlessness and wheezing that vary in frequency and severity from patient to patient. Variable degrees of airflow obstruction, bronchial hyper-responsiveness and underlying inflammation determine the severity of the disease in each patient. The exact nature of the underlying inflammation reflects different aspects of the disease, such as its persistence or intermittency, and whether symptoms are chronic or acute (NHLBI, 2007). The inflammatory response and disease progression underlying asthma is mediated by various types of inflammatory cells and other cellular elements, which may include mast cells, neutrophils, eosinophils, lymphocytes and macrophages

Asthma treatment can be classed as either long-term control medication, aimed at controlling persistent asthma, or quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes inhaled corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, long-acting beta-adrenoceptor agonists (LABA) can be used in combination with ICSs - but not as monotherapies - for moderate or severe persistent asthma. Currently, only two biologics - Xolair (omalizumab) and Nucala (mepolizumab) - are approved as add-on therapy for the treatment of allergic and severe refractory eosinophilic asthma in the Asia-Pacific region.

Asia-Pacific asthma therapeutics market is forecast to grow significantly over the forecast period, from $4.1 billion in 2016 to a projected value of $6 billion by 2023, at a compound annual growth rate (CAGR) of 5.4%

The aging population is growing significantly, which will increase the asthma prevalence in the Asia-Pacific region. In addition, the severity of asthma increases with age, meaning elderly patients require more medications to control their asthma symptoms, which will drive the market (Kopnina, 2012). The prevalence rate of asthma in the Asia-Pacific region in the elderly population is 1.3-15.3%, compared with 5% in the adult population (Song et al., 2014).

The late-stage pipeline contains promising targeted therapies that have the potential for approval and launch during the forecast period. There are four costly biologics that are set to enter the Asia-Pacific asthma therapeutics market: Teva's reslizumab, Sanofi/Regeneron's dupilumab, and AstraZeneca's tralokinumab and benralizumab.

China has a lack of biologic development, despite having the second highest asthma prevalence population after India. In addition, the only approved biologic - Xolair (omalizumab) - is yet to be approved in China, and although it has been available in India since before 2009, its market uptake there is negligible. These findings clearly indicate that there is a significant drug affordability barrier in India and China.

The report "Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market" provides an introduction to asthma, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients. An analysis of current treatment algorithms and options is also included.

In depth, this report provides the following -

  • Provides detailed analysis of the drugs currently marketed for asthma: Arnuity, Seretide/Adoair, Symbicort, Relvar/Breo, Flutiform, Xolair, Montelukast sodium, Spiriva and Nucala. This includes key characteristics, covering safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, prices and overall competitive strength. These products are also compared in a comprehensive heat map.
  • Provides detailed analysis of the pipeline for asthma, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Provides detailed analysis of recent clinical trials in this indication by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the asthma market for the 2016-2023 period, including epidemiology, treatment usage patterns, pricing and market size. The five Asia-Pacific markets are covered, and data are presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for the asthma market.

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, another ICS-LABA combination therapy; and Spiriva, a LAMA.

  • What are the competitive advantages of the existing novel drugs?

With over 290 active pipeline molecules, most of the late-stage investigational drug candidates offer improved dosing regimens and administration routes in comparison to currently marketed products.

  • Which classes of novel drugs are most prominent within the pipeline?
  • How much potential is there for the pipeline to address unmet needs within the asthma market?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (60%).

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2016-2023 forecast period the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a compound annual growth rate of 5.4%, from $4.1 billion to over $6 billion.

x
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Reasons to buy

  • Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action and novelty. Analyze the asthma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within asthma.
  • Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
  • Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Disease Stages
  • 2.7. Prognosis
  • 2.8. Treatment Guidelines and Options
    • 2.8.1. Treatment Algorithm
    • 2.8.2. Pharmacological Treatments
    • 2.8.3. Non-Pharmacological Treatments

3. Marketed Products

  • 3.1. Overview
  • 3.2. ICS for the Maintenance Treatment of Asthma
    • 3.2.1. Arnuity (fluticasone furoate) - GlaxoSmithKline
  • 3.3. ICS-LABA Combination Therapy for the Maintenance Treatment of Asthma
    • 3.3.1. Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) - GlaxoSmithKline
    • 3.3.2. Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-promotion with Astellas Pharma
    • 3.3.3. Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline
    • 3.3.4. Flutiform (fluticasone propionate and formoterol fumarate) - SkyePharma
  • 3.4. Add-on Therapy to ICS or ICS-LABA Therapies for the Maintenance Treatment of Asthma
    • 3.4.1. Xolair (omalizumab) - Novartis and Genentech
    • 3.4.2. Montelukast Sodium - Merck & Co
    • 3.4.3. Spiriva (tiotropium bromide) - Boehringer Ingelheim
    • 3.4.4. Nucala (mepolizumab) - GlaxoSmithKline
  • 3.5. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Analysis

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.3. Pipeline by Molecular Target
  • 4.4. Promising Pipeline Molecules
    • 4.4.1. Reslizumab - Teva Pharmaceutical
    • 4.4.2. Dupilumab - Regeneron/Sanofi
    • 4.4.3. Tralokinumab - AstraZeneca
    • 4.4.4. Benralizumab - AstraZeneca
    • 4.4.5. Fevipiprant - Novartis
  • 4.5. Comparative Efficacy and Safety of Pipeline Products
  • 4.6. Product Competitiveness Framework

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Duration
    • 5.2.1. Clinical Trial Duration by Molecule Type
    • 5.2.2. Clinical Trial Duration by Molecular Target
  • 5.3. Clinical Trial Size
    • 5.3.1. Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
    • 5.3.2. Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
  • 5.4. Summary of Clinical Trial Metrics

6. Multi-Scenario Forecast

  • 6.1. Geographical Markets
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. South Korea
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size
  • 6.7. Japan
    • 6.7.1. Treatment Usage Patterns
    • 6.7.2. Annual Cost of Therapy
    • 6.7.3. Market Size

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. Rising Aging Population and Asthma Risk Factors
    • 7.1.2. Promising Product Pipeline and Launch of First-in-Class Molecules
    • 7.1.3. New Costly Market Entries
    • 7.1.4. Diversified Healthcare Reform to Boost Market Growth
  • 7.2. Barriers
    • 7.2.1. Sales Erosion by Generics
    • 7.2.2. Competition from Traditional Medicines
    • 7.2.3. Treatment Regimen Adherence
    • 7.2.4. Limited Understanding of Underlying Causes
    • 7.2.5. Lack of Awareness and Affordability of High-Cost Biological Products

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type and Molecular Target
    • 8.1.4. Key Licensing Deals
  • 8.2. Co-development Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.2.3. Deal Value by Stage of Development, Molecule Type and Molecular Target
    • 8.2.4. Key Co-development Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Phase of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Investigational New Drug/ Clinical Trial Authorization-Filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Summary of Multi-Scenario Market Forecasts to 2023
    • 9.2.1. Asia-Pacific
    • 9.2.2. China
    • 9.2.3. India
    • 9.2.4. Australia
    • 9.2.5. South Korea
    • 9.2.6. Japan
  • 9.3. References
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 0-4
  • Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 5-11
  • Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Those Aged 12 and over
  • Table 4: Asthma Therapeutics Market, Global, Classification of Asthma Severity According to GINA Guidelines (2002)
  • Table 5: Asthma Therapeutics, Global, Management of Chronic Asthma in Adults and Children Older than Five
  • Table 6: Asthma Diagnosis, Global, Symptoms and Management of Acute Asthma
  • Table 7: Asthma Trials, Global,Clinical Trial Endpoints
  • Table 8: Asthma Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2006-2016
  • Table 9: Asthma Therapeutics Market, Global, Co-development Deals Valued Above $10m, 2006-2016
  • Table 10: Asthma Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
  • Table 11: Asthma Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
  • Table 12: Asthma Therapeutics, Global, All Pipeline Products, IND/CTA-Filed, 2016
  • Table 13: Asthma Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
  • Table 14: Asthma Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
  • Table 15: Asthma Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
  • Table 16: Asthma Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
  • Table 17: Asthma Therapeutics Market, Asia-Pacific, Market Forecast, 2016-2023
  • Table 18: Asthma Therapeutics Market, China, Market Forecast, 2016-2023
  • Table 19: Asthma Therapeutics Market, India, Market Forecast, 2016-2023
  • Table 20: Asthma Therapeutics Market, Australia, Market Forecast, 2016-2023
  • Table 21: Asthma Therapeutics Market, South Korea, Market Forecast, 2016-2023
  • Table 22: Asthma Therapeutics Market, Japan, Market Forecast, 2016-2023

List of Figures

  • Figure 1: Asthma Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
  • Figure 2: Asthma Therapeutics Market, Global, Pipeline, 2016
  • Figure 3: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2016
  • Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
  • Figure 5: Asthma Therapeutics Market, Asia-Pacific, Reslizumab Forecast ($m), 2017-2023
  • Figure 6: Asthma Therapeutics Market, Asia-Pacific, Dupilumab Forecast ($m), 2019-2023
  • Figure 7: Asthma Therapeutics Market, Asia-Pacific, Tralokinumab Forecast ($m), 2019-2023
  • Figure 8: Asthma Therapeutics Market, Asia-Pacific, Benralizumab Forecast ($m), 2018-2023
  • Figure 9: Asthma Therapeutics Market, Asia-Pacific, Fevipiprant Forecast ($m), 2021-2023
  • Figure 10: Asthma Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
  • Figure 11: Asthma Therapeutics Market, Competitor Matrix for Asthma Marketed and Pipeline Products, 2016
  • Figure 12: Asthma Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
  • Figure 13: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2016
  • Figure 14: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2016
  • Figure 15: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2016
  • Figure 16: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2016
  • Figure 17: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecule Type, 2006-2016
  • Figure 18: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecular Target, 2006-2016
  • Figure 19: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2016
  • Figure 20: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2016
  • Figure 21: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 22: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 23: Asthma Therapeutics Market, Asia-Pacific, Treatment Patterns, 2016-2023
  • Figure 24: Asthma Therapeutics Market, Asia-Pacific, Market Size ($bn), 2016-2023
  • Figure 25: Asthma Therapeutics Market, India, Treatment Usage Patterns (million), 2016-2023
  • Figure 26: Asthma Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
  • Figure 27: Asthma Therapeutics Market, India, Market Size ($m), 2016-2023
  • Figure 28: Asthma Therapeutics Market, China, Treatment Usage Patterns, 2016-2023
  • Figure 29: Asthma Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
  • Figure 30: Asthma Therapeutics Market, China, Market Size ($m), 2016-2023
  • Figure 31: Asthma Therapeutics Market, Australia, Treatment Usage Patterns (million), 2016-2023
  • Figure 32: Asthma Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
  • Figure 33: Asthma Therapeutics Market, Australia, Market Size ($m), 2016-2023
  • Figure 34: Asthma Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2016-2023
  • Figure 35: Asthma Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
  • Figure 36: Asthma Therapeutics Market, South Korea, Market Size ($m), 2016-2023
  • Figure 37: Asthma Therapeutics Market, Japan, Treatment Usage Patterns (million), 2016-2023
  • Figure 38: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
  • Figure 39: Asthma Therapeutics Market, Japan, Market Size ($m), 2016-2023
  • Figure 40: Asthma Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
  • Figure 41: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2016
  • Figure 42: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
  • Figure 43: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2016
  • Figure 44: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2016
  • Figure 45: Asthma Therapeutics Market, Global, Co-development Deals by Region, 2006-2016
  • Figure 46: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2016
  • Figure 47: Asthma Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
  • Figure 48: Asthma Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2016
  • Figure 49: Asthma Therapeutics Market, Global, Co-development Deals by Molecular Target, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2016
Back to Top